About me
Kelly Robinson is the Director General of the Pharmaceutical Drugs Directorate at Health Canada. In this role she leads a multidisciplinary team responsible for the authorization of innovative and generic pharmaceuticals, clinical trial evaluation, and the Special Access Program. Kelly has held various leadership positions in drug authorization and post-market surveillance at HC. She has played a pivotal role in advancing national and international regulatory initiatives including fostering alignment between HC and HTAs, enhancing international collaboration through platforms such as Access and ORBIS, and co-chairing the International Coalition of Medicines Regulatory Authorities (ICMRA) Working Group on Real-World Evidence.
